-
11.发明授权Methods for the treatment of neuroleptic and related disorders using ziprasidone metabolites 有权使用齐拉西酮代谢物治疗精神安定药和相关疾病的方法公开(公告)号：US07030142B1
公开(公告)日：2006-04-18
申请号：US09527844
申请日：2000-03-17
Applicant: Timothy J. Barberich , Paul D. Rubin , William E. Yelle
Inventor： Timothy J. Barberich , Paul D. Rubin , William E. Yelle
IPC: A01N43/60 , A61K31/495
CPC classification number: A61K31/495
Abstract: The invention relates to novel methods using, and pharmaceutical compositions comprising, ziprasidone metabolites. The methods and compositions of the invention are suitable for the treatment of neuroleptic and related disorders. The invention further encompasses methods of preparing ziprasidone sulfoxide and ziprasidone sulfone.
Abstract translation: 本发明涉及使用包含齐拉西酮代谢物的药物组合物的新方法。 本发明的方法和组合物适用于治疗精神安定药和相关疾病。 本发明还包括制备齐拉西酮亚砜和齐拉西酮砜的方法。
-
公开(公告)号：US06552045B2
公开(公告)日：2003-04-22
申请号：US10041479
申请日：2002-01-10
Applicant: Paul D. Rubin , Timothy J. Barberich
Inventor： Paul D. Rubin , Timothy J. Barberich
IPC: A61K31445
CPC classification number: A61K31/135 , A61K31/415 , A61K31/445 , A61K38/16 , A61K45/06 , A61K2300/00
Abstract: The invention relates to methods and compositions for the prevention, treatment, or management of gastrointestinal disorders or symptoms thereof, employing two or more agents or compounds to provide a triple site action on 5-HT3 receptors, 5-HT4 receptors, and at least one of H2 receptors and proton pumps.
-
公开(公告)号：US06465470B2
公开(公告)日：2002-10-15
申请号：US09988935
申请日：2001-11-19
Applicant: Timothy J. Barberich , Paul D. Rubin , William E. Yelle
Inventor： Timothy J. Barberich , Paul D. Rubin , William E. Yelle
IPC: A61K3150
CPC classification number: A61K31/496 , C07D249/12
Abstract: The R-isomer of the hydroxy metabolite of nefazodone, R-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.
-
14.发明授权Methods for treating apnea, apnea disorders, bulimia, and other disorders using optically pure (+) norcisapride 失效使用光学纯的（+）诺西沙必利治疗呼吸暂停，呼吸暂停障碍，贪食症和其他障碍的方法
公开(公告)号：US6048879A
公开(公告)日：2000-04-11
申请号：US332196
申请日：1999-06-14
Applicant: Paul D. Rubin , Timothy J. Barberich
Inventor： Paul D. Rubin , Timothy J. Barberich
IPC: A61K31/445 , A61K31/4468 , A61P1/00 , A61P9/06 , A61P11/06 , A61P25/00 , A61P43/00
CPC classification number: A61K31/445 , A61K31/4468
Abstract: Methods for the prevention, treatment or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.
Abstract translation: 使用（+）诺西沙必利或其药学上可接受的盐基本上预防，治疗或治疗呼吸暂停，呼吸暂停障碍，贪食症，肠易激综合征，尿失禁，心动过缓，缓慢性心律失常，晕厥，其他障碍或其症状 没有（ - ）立体异构体。
-
15.发明授权
公开(公告)号：US5589511A
公开(公告)日：1996-12-31
申请号：US228240
申请日：1994-04-15
Applicant: James W. Young , Timothy J. Barberich
Inventor： James W. Young , Timothy J. Barberich
IPC: A61K31/135
CPC classification number: A61K31/135
Abstract: Methods and compositions are disclosed utilizing the pure S(+) isomer of fluoxetine which is a potent antidepressant and appetite suppressant substantially free of unwanted, adverse toxic or psychological effects. In addition, methods and compositions are disclosed utilizing the pure S(+) isomer of fluoxetine which is useful in treating migraine headaches, pain, in particular chronic pain, obsessive-compulsive disorders, sexual dysfunction and memory disorders. Further, methods and compositions for treating a condition alleviated or improved by inhibition of serotonin uptake in serotonergic neurons and platelets in a human using optically pure S(+) fluoxetine are disclosed.
Abstract translation: 公开了使用氟西汀的纯S（+）异构体的方法和组合物，其是有效的抗抑郁药和食欲抑制剂，其基本上不含有害的，不利的毒性或心理作用。 此外，公开了使用氟西汀的纯S（+）异构体的方法和组合物，其可用于治疗偏头痛，疼痛，特别是慢性疼痛，强迫症，性功能障碍和记忆障碍。 此外，公开了通过使用光学纯的S（+）氟西汀在人体中抑制5-羟色胺能神经元和血小板中5-羟色胺摄取而缓解或改善的病症的方法和组合物。
-
Patent Agency Ranking
公开(公告)号：US5382591A
公开(公告)日：1995-01-17
申请号：US118160
申请日：1993-09-08
Applicant: Timothy J. Barberich , Stephen L. Matson , William J. Wechter
Inventor： Timothy J. Barberich , Stephen L. Matson , William J. Wechter
CPC classification number: A61K31/40
Abstract: Methods are disclosed utilizing optically pure R-ketorolac for the treatment of pain, including but not limited to pain associated with toothaches, headaches, sprains, joint pain and surgical pain, for example dental pain (e.g., after periodontal surgery) and ophthalmic pain (e.g., after cataract surgery) while avoiding adverse effects which are associated with the administration of the racemic mixture of ketorolac. The optically pure R-ketorolac is also useful in treating pyrexia while avoiding the adverse effects associated with the administration of the racemic mixture of ketorolac.
Abstract translation: 公开利用光学纯的R-酮咯酸用于治疗疼痛的方法，包括但不限于与牙痛，头痛，扭伤，关节疼痛和手术疼痛相关的疼痛，例如牙痛（例如牙周手术后）和眼痛（ 例如在白内障手术之后），同时避免与给予酮咯酸的外消旋混合物相关的不良反应。 光学纯的R-酮咯酸也可用于治疗发热，同时避免与给予酮咯酸的外消旋混合物相关的不利影响。
-
公开(公告)号：US08877755B2
公开(公告)日：2014-11-04
申请号：US12541686
申请日：2009-08-14
Applicant: Timothy J. Barberich
Inventor： Timothy J. Barberich
IPC: A61K31/4985 , A61P25/14 , A61K31/137 , A61K45/06 , A61K31/425
CPC classification number: A61K45/06 , A61K31/137 , A61K31/425 , A61K31/4985 , A61K2300/00
Abstract: The present invention generally relates to pharmaceutical compositions comprising a dopamine agonist and sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. The pharmaceutical compositions of the invention are useful in the treatment of restless-leg syndrome and periodic-limb-movement disorder, as well as various sleep disorders. In addition, the present invention relates to a method of treating a patient suffering from restless-leg syndrome, periodic-limb-movement disorder, a sleep abnormality, or insomnia, comprising coadministering a therapeutically effective amount of a dopamine agonist and a therapeutically effective amount of a sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone.
Abstract translation: 本发明一般涉及包含多巴胺激动剂和镇静剂的药物组合物。 在优选的实施方案中，多巴胺激动剂是光学纯的（S） - 二甲基甲基西布曲明。 在优选的实施方案中，镇静剂是光学纯的（S） - 佐匹克隆或光学纯的（S）-N-去甲基佐匹克隆。 在优选的实施方案中，多巴胺激动剂是光学纯的（S） - 二甲基甲基西布曲明; 并且镇静剂是光学纯的（S） - 佐匹克隆或光学纯的（S）-N-去甲基佐匹克隆。 本发明的药物组合物可用于治疗不宁腿综合征和周期性肢体运动障碍以及各种睡眠障碍。 此外，本发明涉及治疗患有不宁腿综合征，周期性肢体运动障碍，睡眠异常或失眠的患者的方法，包括共同施用治疗有效量的多巴胺激动剂和治疗有效量 的镇静剂。 在优选的实施方案中，多巴胺激动剂是光学纯的（S） - 二甲基甲基西布曲明。 在优选的实施方案中，镇静剂是光学纯的（S） - 佐匹克隆或光学纯的（S）-N-去甲基佐匹克隆。 在优选的实施方案中，多巴胺激动剂是光学纯的（S） - 二甲基甲基西布曲明; 并且镇静剂是光学纯的（S） - 佐匹克隆或光学纯的（S）-N-去甲基佐匹克隆。
-
公开(公告)号：US20100004251A1
公开(公告)日：2010-01-07
申请号：US12541686
申请日：2009-08-14
Applicant: Timothy J. Barberich
Inventor： Timothy J. Barberich
IPC: A61K31/4985 , A61P25/00
CPC classification number: A61K45/06 , A61K31/137 , A61K31/425 , A61K31/4985 , A61K2300/00
Abstract: The present invention generally relates to pharmaceutical compositions comprising a dopamine agonist and sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. The pharmaceutical compositions of the invention are useful in the treatment of restless-leg syndrome and periodic-limb-movement disorder, as well as various sleep disorders. In addition, the present invention relates to a method of treating a patient suffering from restless-leg syndrome, periodic-limb-movement disorder, a sleep abnormality, or insomnia, comprising coadministering a therapeutically effective amount of a dopamine agonist and a therapeutically effective amount of a sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone.
Abstract translation: 本发明一般涉及包含多巴胺激动剂和镇静剂的药物组合物。 在优选的实施方案中，多巴胺激动剂是光学纯的（S） - 二甲基甲基西布曲明。 在优选的实施方案中，镇静剂是光学纯的（S） - 佐匹克隆或光学纯的（S）-N-去甲基佐匹克隆。 在优选的实施方案中，多巴胺激动剂是光学纯的（S） - 二甲基甲基西布曲明; 并且镇静剂是光学纯的（S） - 佐匹克隆或光学纯的（S）-N-去甲基佐匹克隆。 本发明的药物组合物可用于治疗不宁腿综合征和周期性肢体运动障碍以及各种睡眠障碍。 此外，本发明涉及治疗患有不宁腿综合征，周期性肢体运动障碍，睡眠异常或失眠的患者的方法，包括共同施用治疗有效量的多巴胺激动剂和治疗有效量 的镇静剂。 在优选的实施方案中，多巴胺激动剂是光学纯的（S） - 二甲基甲基西布曲明。 在优选的实施方案中，镇静剂是光学纯的（S） - 佐匹克隆或光学纯的（S）-N-去甲基佐匹克隆。 在优选的实施方案中，多巴胺激动剂是光学纯的（S） - 二甲基甲基西布曲明; 并且镇静剂是光学纯的（S） - 佐匹克隆或光学纯的（S）-N-去甲基佐匹克隆。
-
公开(公告)号：US06384037B1
公开(公告)日：2002-05-07
申请号：US09545602
申请日：2000-04-07
Applicant: Timothy J. Barberich , Paul D. Rubin , William E. Yelle
Inventor： Timothy J. Barberich , Paul D. Rubin , William E. Yelle
IPC: A61K3150
CPC classification number: A61K31/496 , C07D249/12
Abstract: The R-isomer of the hydroxy metabolite of nefazodone, R-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.
-
20.发明授权Methods for treating irritable bowel syndrome using optically pure (+) norcisapride 失效使用光学纯（+）诺西沙必丁治疗肠易激综合征的方法公开(公告)号：US06369079B1
公开(公告)日：2002-04-09
申请号：US09515390
申请日：2000-02-29
Applicant: Paul D. Rubin , Timothy J. Barberich
Inventor： Paul D. Rubin , Timothy J. Barberich
IPC: A61K31445
CPC classification number: A61K31/445 , A61K31/4468
Abstract: Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythnia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (−) stereoisomer.
Abstract translation: 使用（+）诺西沙必利或其药学上可接受的盐的预防，治疗或治疗呼吸暂停，呼吸暂停障碍，贪食症，肠易激综合征，尿失禁，心动过缓，缓慢性心律失调，晕厥，其他障碍或其症状的方法， 基本上不含（ - ）立体异构体。
-
-
-
-
-
-
-
-
-
Search Results
34
records
(took 0.02 seconds)
